Sage Therapeutics Announces Promising Zuranolone Phase 3 Findings for Major Depression
New Depression Drug Likened to an Antibiotic Sent Stocks Surging
Sage Therapeutics Inc Shares Fall 0.3% Below Previous 52-Week Low - Market Mover | Nasdaq
Sage Therapeutics (SAGE) - price stock, stock chart, quote online, dividends, stock analysis, stock news, company profile | Finrange.com
Biopharmaceutical Company for Brain Health Disorders - Sage Therapeutics
Sage Therapeutics: Steady Recovery After Biogen Deal (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics' stock tanks as Phase III depression study misses primary endpoint - MedCity News
Sage Therapeutics, Biogen's Zuranolone Plus SOC Rapidly and Significantly Reduced Depressive Symptoms in Phase 3 CORAL
Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During “Sage FutureCast” | Business Wire
Sage Therapeutics Tumbles After Depression Drug-Trial Results - TheStreet
Did SAGE Therapeutics Just Break the CNS Curse? | BioSpace
Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care
Is Sage Therapeutics a Buy? | The Motley Fool
Biopharmaceutical Company for Brain Health Disorders - Sage Therapeutics
Sage Therapeutics: Biogen's Backing May See It Through (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Stock Forecast, Price & News (NASDAQ:SAGE)
SAGE Stock Price and Chart — NASDAQ:SAGE — TradingView
While Sage Therapeutics sees a window for depression drug, market is skeptical - MedCity News
Biopharmaceutical Company for Brain Health Disorders - Sage Therapeutics
Biogen Gives Sage Therapeutics $1.5 Billion In Deal To Develop Depression And Tremor Treatments | The Healthcare Technology Report.
Positive Results in Hand, Sage Scraps Two Phase III Zuranolone Studies | BioSpace
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Sage Therapeutics Rises After Swing to Profit on Biogen Deal - TheStreet
Sage Therapeutics Appoints Chris Benecchi as Chief Commercial Officer
Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study
